Search

Your search keyword '"Magaret, Amalia"' showing total 452 results
Start Over Author "Magaret, Amalia" Language english
452 results on '"Magaret, Amalia"'

5. CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions

Author

Celum, Connie, Wald, Anna, Lingappa, Jairam R., Baeten, Jared M., Campbell, Mary S., Corey, Lawrence, Coombs, Robert W., Hughes, James P., Magaret, Amalia, McElrath, M. Juliana, Morrow, Rhoda, Mullins, James I., Coetzee, David, Fife, Kenneth, Were, Edwin, Essex, Max, Makhema, Joseph, Katabira, Elly, Ronald, Allan, Bukusi, Elizabeth, Cohen, Craig, Kapiga, Saidi, Manongi, Rachel, Farquhar, Carey, John-Stewart, Grace, Kiarie, James, Delany-Moretlwe, Sinead, Rees, Helen, de Bruyn, Guy, Gray, Glenda, McIntyre, James, Mugo, Nelly Rwamba, Donnell, Deborah, Frenkel, Lisa, Hendrix, Craig W., Tumwesigye, Elioda, Ndase, Patrick, Bukusi, Eliabeth, Wangisi, Jonathan, Campbell, James, Tappero, Jordan, Richert-Spuhler, Laura E., Mar, Corinne M., Shinde, Paurvi, Wu, Feinan, Hong, Ting, Greene, Evan, Hou, Sharon, Thomas, Katherine, Gottardo, Raphael, Mugo, Nelly, and Lund, Jennifer M.

Published
2021
Full Text
View/download PDF

8. Respiratory Syncytial Virus Infection in Homeless Populations, Washington, USA

Author

Boonyaratanakornkit, Jim, Ekici, Seda, Magaret, Amalia, Gustafson, Kathryn, Scott, Emily, Haglund, Micaela, Kuypers, Jane, Pergamit, Ronald, Lynch, John, and Chu, Helen Y.

Subjects
Influenza vaccines, Diseases -- Risk factors, Homelessness, Medical research, Influenza -- Risk factors, Elderly, Homeless persons, Meropenem, Health
Abstract

Respiratory syncytial virus (RSV) is increasingly recognized as a major pathogen in adults and shows a disease burden comparable to that for influenza (1). No vaccine is currently available. However, [...]

Published
2019
Full Text
View/download PDF

20. Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples

Author

Partners in Prevention HSV/HIV Transmission Study Team, Magaret, Amalia S., Mujugira, Andrew, Hughes, James P., Lingappa, Jairam, Bukusi, Elizabeth A., DeBruyn, Guy, Delany-Moretlwe, Sinead, Fife, Kenneth H., Gray, Glenda E., Kapiga, Saidi, Karita, Etienne, Mugo, Nelly R., Rees, Helen, Ronald, Allan, Vwalika, Bellington, Were, Edwin, Celum, Connie, and Wald, Anna

Published
2016

29. Human metapneumovirus and other respiratory viral infections during pregnancy and birth, Nepal

Author

Lenahan, Jennifer L., Englund, Janet A., Katz, Joanne, Kuypers, Jane, Wald, Anna, Magaret, Amalia, Tielsch, James M., Khatry, Subarna K., LeClerq, Stephen C., Shrestha, Laxman, Steinhoff, Mark C., and Chu, Helen Y.

Subjects
Respiratory insufficiency -- Risk factors -- Research, RNA viruses -- Risk factors -- Research, Pregnancy -- Health aspects -- Analysis, Health
Abstract

Human metapneumovirus (HMPV), a paramyxovirus discovered in 2001, is a previously unrecognized cause of respiratory infections in infants, children, and adults (1). HMPV is estimated to cause 5%-25% of respiratory [...]

Published
2017
Full Text
View/download PDF

33. A cross-sectional analysis of Trichomonas vaginalis infection among heterosexual HIV-1 serodiscordant African couples

Author

Bochner, Aaron F, Baeten, Jared M, Rustagi, Alison S, Nakku-Joloba, Edith, Lingappa, Jairam R, Mugo, Nelly R, Bukusi, Elizabeth A, Kapiga, Saidi, Delany-Moretlwe, Sinead, Celum, Connie, Barnabas, Ruanne V, Celum, Connie, Baeten, Jared M, Donnell, Deborah, Coombs, Robert W, Frenkel, Lisa, Hendrix, Craig W, Lingappa, Jairam, McElrath, M Juliana, Fife, Kenneth, Were, Edwin, Tumwesigye, Elioda, Ndase, Patrick, Katabira, Elly, Katabira, Elly, Ronald, Allan, Bukusi, Elizabeth, Cohen, Craig, Wangisi, Jonathan, Campbell, James, Tappero, Jordan, Kiarie, James, Farquhar, Carey, John-Stewart, Grace, Mugo, Nelly Rwamba, Campbell, James, Tappero, Jordan, Wangisi, Jonathan, Celum, Connie, Wald, Anna, Lingappa, Jairam R, Baeten, Jared M, Campbell, Mary S, Corey, Lawrence, Coombs, Robert W, Hughes, James P, Magaret, Amalia, McElrath, M Juliana, Morrow, Rhoda, Mullins, James I, Coetzee, David, Fife, Kenneth, Were, Edwin, Essex, Max, Makhema, Joseph, Katabira, Elly, Ronald, Allan, Bukusi, Elizabeth, Cohen, Craig, Kapiga, Saidi, Manongi, Rachel, Farquhar, Carey, John-Stewart, Grace, Kiarie, James, Allen, Susan, Kanweka, William, Allen, Susan, Inambao, Mubiana, Delany-Moretlwe, Sinead, Rees, Helen, Bruyn, Guy de, Gray, Glenda, and McIntyre, James

Published
2017
Full Text
View/download PDF

35. Genital Herpes Simplex Virus Type 2 Suppression With Valacyclovir Is Not Associated With Changes in Nugent Score or Absolute Abundance of Key Vaginal Bacteria.

Author

Babu, Tara M, Srinivasan, Sujatha, Magaret, Amalia, Proll, Sean, Karita, Helen Stankiewicz, Wallis, Jacqueline M, Selke, Stacy, Varon, Dana, Pholsena, Thepthara, Fredricks, David, Marrazzo, Jeanne, Wald, Anna, and Johnston, Christine

Abstract

Background In women, genital herpes simplex virus type 2 (HSV-2) infection is associated with increased risk for recurrent bacterial vaginosis (BV), but causal relationships are unclear. Methods Women with a self-reported history of BV and HSV-2 seropositivity self-collected vaginal and anogenital swabs for 2 nonconsecutive 28-day periods, in the absence or presence of valacyclovir suppressive therapy (500 mg daily). HSV polymerase chain reaction was performed on anogenital swabs; vaginal swabs were used for assessment of BV by Nugent score and quantification of vaginal microbiota. Days with BV, defined by Nugent score ≥7, were compared during the observational period and valacyclovir treatment. Results Forty-one women collected swabs for a median of 28 days (range, 20–32 days) each study period. The HSV-2 shedding rate decreased from 109 of 1126 days (9.7%) presuppression to 6 of 1125 days (0.05%) during valacyclovir (rate ratio [RR], 0.06 [95% confidence interval {CI},.02–.13]). BV occurred on 343 of 1103 days (31.1%) during observation and 302 of 1091 days (27.7%) during valacyclovir (RR, 0.90 [95% CI,.68–1.20]). The median per-person Nugent score was 3.8 during observation and 4.0 during valacyclovir. Average log10 concentrations of vaginal bacterial species did not change significantly during valacyclovir treatment. Conclusions Short-term HSV-2 suppression with valacyclovir did not significantly affect the Nugent score or the vaginal microbiome despite potent suppression of HSV-2 shedding. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection.

Author

Johnston, Christine, Magaret, Amalia, Son, Hyunju, Stern, Michael, Rathbun, Molly, Renner, Daniel, Szpara, Moriah, Gunby, Sarah, Ott, Mariliis, Jing, Lichen, Campbell, Victoria L., Huang, Meei-li, Selke, Stacy, Jerome, Keith R., Koelle, David M., and Wald, Anna

Subjects
*EVALUATION research, *VIRAL physiology, *RESEARCH funding, *HERPESVIRUSES, *HIV infections, *HERPES genitalis, *GENITALIA, *LONGITUDINAL method, *RESEARCH, *HERPES simplex, *COMPARATIVE studies
Abstract

Importance: Herpes simplex virus type 1 (HSV-1) is the leading cause of first-episode genital herpes in many countries.Objective: To inform counseling messages regarding genital HSV-1 transmission, oral and genital viral shedding patterns among persons with first-episode genital HSV-1 infection were assessed. The trajectory of the development of HSV-specific antibody and T-cell responses was also characterized.Design, Setting, and Participants: Prospective cohort followed up for up to 2 years, with 82 participants followed up between 2013 and 2018. Participants were recruited from sexual health and primary care clinics in Seattle, Washington. Persons with laboratory-documented first-episode genital HSV-1 infection, without HIV infection or current pregnancy, were referred for enrollment.Exposures: First-episode genital HSV-1 infection.Main Outcomes and Measures: Genital and oral HSV-1 shedding and lesion rates at 2 months, 11 months, and up to 2 years after initial genital HSV-1 infection. Participants self-collected oral and genital swabs for HSV polymerase chain reaction testing for 30 days at 2 and 11 months and up to 2 years after diagnosis of genital HSV-1. Blood samples were collected at serial time points to assess immune responses to HSV-1. Primary HSV-1 infection was defined as absent HSV antibody at baseline or evolving antibody profile using the University of Washington HSV Western Blot. HSV-specific T-cell responses were detected using interferon γ enzyme-linked immunospot.Results: Among the 82 participants, the median (range) age was 26 (16-64) years, 54 (65.9%) were women, and 42 (51.2%) had primary HSV-1 infection. At 2 months, HSV-1 was detected from the genital tract in 53 participants (64.6%) and in the mouth in 24 participants (29.3%). Genital HSV-1 shedding was detected on 275 of 2264 days (12.1%) at 2 months and declined significantly to 122 of 1719 days (7.1%) at 11 months (model-predicted rate, 6.2% [95% CI, 4.3%-8.9%] at 2 months vs 3.2% [95% CI, 1.8%-5.7%] at 11 months; relative risk, 0.52 [95% CI, 0.29-0.93]). Genital lesions were rare, reported on 65 of 2497 days (2.6%) at 2 months and 72 of 1872 days (3.8%) at 11 months. Oral HSV-1 shedding was detected on 88 of 2247 days (3.9%) at 2 months. Persons with primary HSV-1 infection had a higher risk of genital shedding compared with those with nonprimary infection (model-predicted rate, 7.9% [95% CI, 5.4%-11.7%] vs 2.9% [95% CI, 1.7%-5.0%]; relative risk, 2.75 [95% CI, 1.40-5.44]). Polyfunctional HSV-specific CD4+ and CD8+ T-cell responses were maintained during the follow-up period.Conclusions and Relevance: Genital HSV-1 shedding was frequent after first-episode genital HSV-1, particularly among those with primary infection, and declined rapidly during the first year after infection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results